Design, synthesis, and biological evaluation of dinuclear bismuth(III) complexes with Isoniazid-derived Schiff bases.

J Inorg Biochem

Hunan Provincial Key Laboratory of Xiangnan Rare-Precious Metals Compounds and Applications, School of Chemistry and Environmental Science, Xiangnan University, Chenzhou 423000, Hunan Province, China.

Published: October 2022

Four dinuclear bismuth(III) Schiff-base complexes bearing Schiff-base ligands have been synthesized and structurally characterized by single-crystal X-ray diffraction, elemental analysis, and spectral techniques (FT-IR, NMR and MS). The analytical data reveal the bismuth(III) complexes possess 1:1 metal-ligand ratios. In vitro biological studies have revealed that bismuth(III) complexes displayed much higher antibacterial and antitumor activities than their parent ligands, which involves two gram-negative (S. aureus, B. subtili) and two gram-positive (E. coli, P. aeruginosa) bacteria, and human gastric cancer SNU-16 cells. The power-time curves of S. pombe exposed to tested compounds were detected by bio-microcalorimetry. Some thermokinetic parameters (k, Pt and Q) were derived based on the metabolic power-time curves, and their quantitative relationships with the concentrations (c) were further discussed.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jinorgbio.2022.111931DOI Listing

Publication Analysis

Top Keywords

bismuthiii complexes
12
dinuclear bismuthiii
8
power-time curves
8
design synthesis
4
synthesis biological
4
biological evaluation
4
evaluation dinuclear
4
bismuthiii
4
complexes
4
complexes isoniazid-derived
4

Similar Publications

New bismuth (III) complexes with acetophenone-4-methyl-3-thiosemicarbazone (L) and halogens (Cl and Br) in both bridging and terminal positions have been synthesized and structurally characterized using single-crystal X-ray diffraction. The pure complexes (Cl or Br) were found to be highly isostructural, which motivated our attempts to create solid solutions of these complexes. A series of such compounds was prepared using various procedures and stoichiometries.

View Article and Find Full Text PDF
Article Synopsis
  • The development of theranostic agents using alpha emitters addresses a significant clinical need, focusing on combining therapeutic and diagnostic functions in medicine.* -
  • A new ligand, macropa-F, was created to effectively bind to alpha therapeutic radiometals, and its properties were tested with lead-203 and bismuth-207 as substitutes for actual alpha-emitting isotopes.* -
  • The resulting fluorine-18 and radiometal complexes demonstrated high stability in human serum for several days, showcasing a promising approach for theranostic applications in medicine.*
View Article and Find Full Text PDF

Here we demonstrate the hydrohalogenation reactions of HDDA benzynes promoted by BiX reagents for the generation of complex aryl halides. All three bismuth(III) halides can act as the source for their respective halides, i.e.

View Article and Find Full Text PDF

The discovery and utilization of main-group element catalysts that behave similarly to transition metal (TM) complexes have become increasingly active areas of investigation in recent years. Here, we report a series of Lewis acidic bismuth(III) complexes that allow for the catalytic allylic C(sp)-H functionalization of olefins via an organometallic complexation-assisted deprotonation mechanism to generate products containing new C-C bonds. This heretofore unexplored mode of main-group reactivity was applied to the regioselective functionalization of 1,4-dienes and allylbenzene substrates.

View Article and Find Full Text PDF

Bismuth(III) complexes have been reported to act as inhibitors of the enzyme urease, ubiquitously present in soils and implicated in the pathogenesis of several microorganisms. The general insolubility of Bi(III) complexes in water at neutral pH, however, is an obstacle to their utilization. In our quest to improve the solubility of Bi(III) complexes, we selected a compound reported to inhibit urease, namely [Bi(HEDTA)]·2HO, and co-crystallized it with (i) racemic DL-histidine to obtain the conglomerate [Bi(HEDTA)(μ-D-His)]·6HO + [Bi(HEDTA)(μ-L-His)]·6HO, (ii) enantiopure L-histidine to yield [Bi(HEDTA)(μ-L-His)]·6HO, and (iii) cytosine to obtain [Bi(HEDTA)]·Cyt·2HO.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!